Race Oncology : ASX Small and Mid-Cap Conference Presentation

For personal use only

ASX Announcement

Race ASX Small and Mid-Cap Conference Presentation

15 March 2022 - Race Oncology Limited ("Race") is pleased to be presenting at the 2022 ASX Small and Mid-Cap Conference, which is being held virtually on 15 & 16 March 2022.

The presentation summarises significant recent news in regards the clinical development of our lead oncology drug, Zantrene®, including:

• The recently reported results from our clear cell renal cell carcinoma (a dangerous form of kidney cancer) preclinical program, which found that Zantrene killed a range of kidney cancer cells both on its own and in combination with existing cancer treatments (ASX Announcement: 10 March 2022).
• An update on Race's cardioprotection program following the discovery late last year that Zantrene protects heart muscle cells from anthracycline (specifically doxorubicin) induced cell death while improving anti-cancer activity.

A copy of the presentation is appended with this cover note. Race will be presenting at the ASX Small and Mid-Cap Conference at 11.30 am AEST on Wednesday, 16 March 2022.

Registration for the virtual event is available here: https://eventfrog.eventsair.com/asx- small-and-mid-cap-conference-2022-march/registration/Site/Register

- ENDS -

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race Oncology Ltd ABN 61 149 318 749

1

Registered office: L36, 1 Macquarie Place, Sydney NSW 2000

www.raceoncology.com

For personal use only

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

Release authorised by:	Media contact:
Phil Lynch, CEO/MD on behalf	Jane Lowe
of the Race Board of Directors	[phone]
[e-mail]	[e-mail]

Race Oncology Ltd ABN 61 149 318 749

2

Registered office: L36, 1 Macquarie Place, Sydney NSW 2000

www.raceoncology.com

r personal use only

RNA-DIRECTED THERAPEUTICS

TO TREAT CANCER AND PROTECT THE HEART

Presentation - ASX Small Caps Conference

March 16 2022

r personal use only

DISCLAIMER

Investment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in Race, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary. This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

RACE ONCOLOGY LIMITED (ASX:RAC)		2		INVESTOR PRESENTATION

r personal use only

CORPORATE SNAPSHOT

ISSUED CAPITAL

Shares1	159.5m
Options1	20.6m
Shareholders2	9,476
MARKET CAPITALISATION
Share price1	$2.54
Market value1	$405.1m
Cash2	$37.1m
Enterprise value	$368m
SIGNIFICANT SHAREHOLDERS
Dr Daniel Tillett (Director & CSO)	8.5%
Dr John Cullity (Chairman)	5.1%
Merchant Opportunities Fund	4.8%

1. As at 14 March 2022. Includes 7.04 million $4.50 Bonus Options expiring 16 May 2022
2. As at 30 Dec 2021

RACE ONCOLOGY LIMITED (ASX:RAC)

ASX 24 MONTH PERFORMANCE

3		INVESTOR PRESENTATION